Table 1 Baseline clinical data of patients with BRVO and healthy control participants in this study
Parameters | BRVO eyes (n = 54) | Fellow eyes (n = 54) | Healthy control eyes (n = 30) | P (BRVO vs. fellow) | P (fellow vs. control) |
|---|---|---|---|---|---|
Age (years, range) | 60.56 ± 9.18 (45–79) | 60.92 ± 5.22 (50–73) | NA | 0.85 | |
Sex (male/female) | 35/19 | 18/12 | NA | 0.66 | |
Eye dominance (OD/OS) | 35/19 | 19/35 | 14/16 | NA | 0.30 |
Hypertension (+/−) | 31/23 | 13/17 | NA | 0.22 | |
Mean systolic pressure (mmHg) | 132.81 ± 13.67 | 129.68 ± 10.95 | NA | 0.32 | |
Mean diastolic pressure (mmHg) | 78.31 ± 8.78 | 79.52 ± 5.65 | NA | 0.53 | |
IOP (mmHg) | 14.41 ± 3.52 | 15.06 ± 3.00 | 15.84 ± 2.75 | 0.15 | 0.28 |
Refractive error (SE, diopter) | − 0.15 ± 1.52 | − 0.42 ± 1.55 | − 0.24 ± 1.28 | 0.10 | 0.63 |
Duration of symptoms (months) | 1.50 ± 1.03 | NA | NA | NA | NA |
Type (ischemia/non-ischemia) | 36/18 | NA | NA | NA | NA |
Occlusion area (ST/IT) | 38/16 | NA | NA | NA | NA |
Quadrants measured (ST/IT) | 16/38 | 16/38 | 9/21 | NA | 0.97 |
BCVA (ETDRS letters, Snellen equivalent) | 53.56 ± 16.09 (20/90) | 84.30 ± 2.49 (20/21) | 84.60 ± 1.04 (20/20) | < 0.01 | 0.56 |
CRT (μm) | 581.70 ± 191.90 | 257.41 ± 26.21 | 260.60 ± 23.17 | < 0.01 | 0.60 |
FAZ area (mm2) | 0.41 ± 0.15 | 0.35 ± 0.09 | 0.32 ± 0.10 | < 0.01 | 0.16 |
First-order artery | Â | Â | Â | Â | Â |
 PaCFZ area (mm2) | 0.54 ± 0.18 | 0.45 ± 0.15 | 0.42 ± 0.16 | < 0.01 | 0.53 |
 Artery area (mm2) | 0.49 ± 0.20 | 0.53 ± 0.14 | 0.51 ± 0.16 | 0.20 | 0.50 |
 P/A ratio | 1.14 ± 0.22 | 0.84 ± 0.22 | 0.83 ± 0.16 | < 0.01 | 0.78 |
Second-order artery | Â | Â | Â | Â | Â |
 PaCFZ area (mm2) | 0.96 ± 0.48 | 0.75 ± 0.25 | 0.73 ± 0.25 | < 0.01 | 0.78 |
Artery area (mm2) | 0.60 ± 0.38 | 0.65 ± 0.23 | 0.64 ± 0.24 | 0.25 | 0.88 |
 P/A ratio | 1.83 ± 0.55 | 1.25 ± 0.53 | 1.18 ± 0.29 | < 0.01 | 0.59 |
No. of IVR injections (range) | 4.98 ± 2.17 (3–10) | NA | NA | NA | NA |